Motility News

The American Neurogastronterology and Motility Task Force developed recommendations for resuming gastrointestinal motility procedures during COVID-19, which were published in the American Journal of Gastroenterology.

Baseline features of gastroparesis, identified with gastric motility testing, may help identify patient risk for more severe longitudinal symptoms and worse quality of life, according to study results.

Recently, the small intestine bacterial overgrowth breath test was launched by Cedars-Sinai to diagnose small intestine bacterial overgrowth related to irritable bowel syndrome.

Remicade and Entyvio were effective for the treatment of patients with checkpoint inhibitor-induced enterocolitis, according to the results of a meta-analysis.

Researchers from Brazil found patients on hemodialysis who reported a lower frequency of fruit intake were more likely to have constipation than those who consumed more fruit.

While gastrointestinal symptoms like anorexia and diarrhea are common in both patients with COVID-19 and those without, these symptoms plus a loss of smell, taste and fever were 99% specific for COVID-19, according to a study published in Gastroenterology.

Peripherally acting mu-opioid receptor antagonists helped patients with opioid-induced constipation achieve therapeutic response, according to a meta-analysis published in Alimentary Pharmacology & Therapeutics.

In this exclusive video, Lynn R. Webster, MD, from PRA Health Sciences in Salt Lake City, discusses his study from Digestive Disease Week that explored the impact of Relistor, a mu-opioid receptor agonist, on all-cause mortality in patients with opioid-induced constipation.

Results from a real-word study showed fecal microbiota transplantation for Clostridioides difficile infection was highly effective, with little serious adverse events related to the procedure, according to data from Digestive Disease Week.

The American Gastroenterological Association released guidance on consultative management of COVID-19 among patients with gastrointestinal and liver manifestations.